<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Sambhara, DVM, PhD, Influenza Division, National Center for Immunization and" exact="Respiratory" post="Diseases, Centers for Disease Control and Prevention, Immunology and"/>
 <result pre="Division, National Center for Immunization and Respiratory Diseases, Centers for" exact="Disease" post="Control and Prevention, Immunology and Pathogenesis Branch, 1600 Clifton"/>
 <result pre="BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract Retinoic acid-inducible gene-I (RIG-I) is a" exact="cytosolic" post="pathogen sensor that is crucial against a number of"/>
 <result pre="cytosolic pathogen sensor that is crucial against a number of" exact="viral" post="infections. Many viruses have evolved to inhibit pathogen sensors"/>
 <result pre="influenza, nonstructural protein 1 (NS1) suppresses RIG-I function, leading to" exact="viral" post="replication, morbidity, and mortality. We show that silencing NS1"/>
 <result pre="We show that silencing NS1 with in-vitro-transcribed 5′-triphosphate containing NS1" exact="short" post="hairpin RNA (shRNA) (5′-PPP-NS1shRNA), designed using the conserved region"/>
 <result pre="only prevented NS1 expression but also induced RIG-I activation and" exact="type I" post="interferon (IFN) expression, resulting in an antiviral state leading"/>
 <result pre="in prophylactic and therapeutic settings resulted in significant inhibition of" exact="viral" post="replication following viral challenge in vivo in mice with"/>
 <result pre="therapeutic settings resulted in significant inhibition of viral replication following" exact="viral" post="challenge in vivo in mice with corresponding increases of"/>
 <result pre="in older adults and those with underlying medical conditions. Influenza" exact="infections" post="resulted in 48.8 million illnesses, more than 22.7 million"/>
 <result pre="neuraminidase inhibitors, are the drugs of choice to treat influenza" exact="viral" post="infections.2 To have the antiviral effects, oseltamivir, the neuraminidase"/>
 <result pre="new drug, baloxavir marboxil, marketed as Xofluza, which inhibits influenza" exact="viral" post="polymerase, was approved to treat influenza infections, almost two"/>
 <result pre="the cell surface, in vesicles, or in the cytosol.16 Among" exact="cytosolic" post="pathogen sensors, we and others have shown that retinoic"/>
 <result pre="a significant proportion of the human population has defects in" exact="type 1" post="interferon (IFN) induction, as well as activation pathways, the"/>
 <result pre="silences NS1 (needed for the population that has defects in" exact="type 1" post="IFN induction/activation pathways) and at the same time it"/>
 <result pre="the same time it activates the antiviral RIG-I pathway (in" exact="type 1" post="IFN-sufficient population), and demonstrate that it is efficacious against"/>
 <result pre="IFN-sufficient population), and demonstrate that it is efficacious against influenza" exact="virus infection" post="in prophylactic and therapeutic settings, both in vitro and"/>
 <result pre="population), and demonstrate that it is efficacious against influenza virus" exact="infection" post="in prophylactic and therapeutic settings, both in vitro and"/>
 <result pre="of 12 different influenza viruses. Sequence alignment results revealed nine" exact="short" post="stretches of sequence that were the most conserved among"/>
 <result pre="to shRNA attack by predicting stretches with minimal to no" exact="secondary" post="structure that would impede shRNA binding (Figure 1A).27 The"/>
 <result pre="NS1 target sense sequence, stem loop, target antisense sequence, and" exact="hepatitis" post="delta virus (HDV) ribozyme (Figure 1B). The purpose of"/>
 <result pre="a higher probability of access for shRNA attack based on" exact="secondary" post="structure. Orange shaded regions indicate domains with ≥97% homology"/>
 <result pre="(in blue), loop (in green), target antisense (in gray), and" exact="hepatitis" post="delta virus (HDV) ribozyme (in pink). Both ends of"/>
 <result pre="and Suppresses NS1 Expression in A549 Cells following Influenza Virus" exact="Infection" post="We and others have shown the antiviral potential of"/>
 <result pre="the lack of NS1 silencing ability, as well as the" exact="absence of" post="the 5′-PPP moiety (Figure 1E). Differentiating NS1 Silencing versus"/>
 <result pre="the antiviral responses mediated by RIG-I activation and induction of" exact="type 1" post="IFN and its interaction with type 1 IFN receptors"/>
 <result pre="and induction of type 1 IFN and its interaction with" exact="type 1" post="IFN receptors due to the presence of the 5′-PPP"/>
 <result pre="groups and then infected with A/Brisbane/59/2007 at a multiplicity of" exact="infection" post="(MOI) of 1.0 at 6 and 24 h post-transfection."/>
 <result pre="cells treated with NS1shRNA uncapped or m7G-capped followed by influenza" exact="virus infection" post="as compared with controls. However, no reduction in NS1"/>
 <result pre="treated with NS1shRNA uncapped or m7G-capped followed by influenza virus" exact="infection" post="as compared with controls. However, no reduction in NS1"/>
 <result pre="both by suppression of NS1 expression and by induction of" exact="type 1" post="IFN-mediated antiviral effects. Figure 2 Differentiating NS1 Silencing and"/>
 <result pre="1 IFN-mediated antiviral effects. Figure 2 Differentiating NS1 Silencing and" exact="Type 1" post="IFN-Mediated Antiviral Effects Vero cells (1 × 106) were"/>
 <result pre="hours post-infection, supernatants and cell lysates were collected to determine" exact="viral" post="titers in plaque assay using Madin Darby canine kidney"/>
 <result pre="exception of m7G-capped scrambled and m7G-capped control constructs significantly reduced" exact="viral" post="titers when compared with control, with inhibitions ranging from"/>
 <result pre="3A). For example, NS1shRNA containing a 5′-PPP moiety significantly reduced" exact="viral" post="titers by about 4 logs at the 6-h time"/>
 <result pre="well as direct inhibition of NS1 transcripts. m7G-capped NS1shRNA inhibited" exact="viral" post="titers by about 3 logs, and this inhibition was"/>
 <result pre="synergistically in dual-functioning 5′-PPP-NS1shRNA. 5′-PPP-containing scrambled shRNA construct did reduce" exact="viral" post="titers through RIG-I activation; however, the reduction in viral"/>
 <result pre="reduce viral titers through RIG-I activation; however, the reduction in" exact="viral" post="titers hovered around 3 logs for all time points"/>
 <result pre="(Figure 3A). Similarly, the positive control shRNA, Is9.2, also reduced" exact="viral" post="titers by about 3 logs, and this inhibition was"/>
 <result pre="this inhibition was mediated through RIG-I activation. The inhibition of" exact="viral" post="titers correlated with the significant inhibition (80%–90%) of NS1"/>
 <result pre="by quantitative real-time PCR. Cell supernatants were collected for detecting" exact="viral" post="titers by plaque assay. (A–D) Viral titer (A), relative"/>
 <result pre="were collected for detecting viral titers by plaque assay. (A–D)" exact="Viral" post="titer (A), relative mRNA expression of (B) NS1, (C)"/>
 <result pre="h post-infection, the cells were treated with shRNAs (Figure 4)." exact="Viral" post="titers were significantly lower (&amp;gt;3 logs reduction) in infected"/>
 <result pre="were treated with shRNAs (Figure 4). Viral titers were significantly" exact="lower" post="(&amp;gt;3 logs reduction) in infected cells treated with NS1shRNA"/>
 <result pre="scrambled shRNA nor m7G-capped Is9.2 RNA had any impact on" exact="viral" post="titers. NS1shRNAs with or without 5′-PPP were able to"/>
 <result pre="was not seen at 12- or 24-h time points during" exact="infection" post="(Figure 4C). Interestingly, treatment of infected cells with NS1shRNA"/>
 <result pre="by quantitative real-time PCR, and supernatants were collected for detecting" exact="viral" post="titers by plaque assay. (A–D) Viral titers in the"/>
 <result pre="were collected for detecting viral titers by plaque assay. (A–D)" exact="Viral" post="titers in the supernatants measured by plaque assay in"/>
 <result pre="its capped counterparts, as well as scrambled shRNA, to reduce" exact="viral" post="titers both in a prophylactic and a therapeutic model"/>
 <result pre="PBS. We harvested lungs on day 4 post-infection to measure" exact="viral" post="titers by plaque assay and RIG-I, NS1, IFN-β, IFN-λ,"/>
 <result pre="h prior to virus infection) in a prophylactic model reduced" exact="viral" post="titers by 2 logs (or 90% reduction) (Figure 5A)"/>
 <result pre="results in NS1 suppression and RIG-I activation, and suppresses influenza" exact="viral" post="replication significantly. However, single-dose administration on the same day"/>
 <result pre="replication significantly. However, single-dose administration on the same day of" exact="infection" post="or 24 h post-infection, albeit less effective than day"/>
 <result pre="day −1 administration, did result in a significant decrease in" exact="viral" post="replication and NS1 expression with corresponding increases in RIG-I,"/>
 <result pre="harvested on day 4. (A–F) Lungs were analyzed for (A)" exact="viral" post="titers by plaque assay, and mRNA expression of (B)"/>
 <result pre="women, and people with certain medical conditions, such as cancer," exact="chronic" post="lung disease, heart disease, diabetes, and blood, lung, or"/>
 <result pre="and people with certain medical conditions, such as cancer, chronic" exact="lung disease," post="heart disease, diabetes, and blood, lung, or kidney disorders."/>
 <result pre="with certain medical conditions, such as cancer, chronic lung disease," exact="heart" post="disease, diabetes, and blood, lung, or kidney disorders. Current"/>
 <result pre="influenza vaccines in young children and older adults is comparatively" exact="lower" post="due to weaker immune systems in these populations. Hence,"/>
 <result pre="drugs play a central part in the treatment of influenza" exact="viral" post="infections. Three classes of drugs are licensed to treat"/>
 <result pre="in 1966), neuraminidase inhibitors (oseltamivir approved in 2000), and a" exact="viral" post="polymerase inhibitor (baloxavir marboxil [Xofluza] approved in 2018).2,3,36 However,"/>
 <result pre="that are resistant against currently licensed drugs. Instead of targeting" exact="viral" post="components to inhibit viral replication, we targeted host innate"/>
 <result pre="currently licensed drugs. Instead of targeting viral components to inhibit" exact="viral" post="replication, we targeted host innate immune components to create"/>
 <result pre="innate immune components to create an antiviral state to suppress" exact="viral" post="growth. We have shown earlier that activating the RIG-I"/>
 <result pre="demonstrated that activation of the RIG-I pathway also inhibited Ebola" exact="viral" post="replication.23 Furthermore, the viruses did not develop resistance to"/>
 <result pre="function of NS1 silencing and RIG-I activation rather than other" exact="viral" post="structural components because NS1 is the viral virulence factor"/>
 <result pre="rather than other viral structural components because NS1 is the" exact="viral" post="virulence factor that suppresses host innate immune responses to"/>
 <result pre="virulence factor that suppresses host innate immune responses to facilitate" exact="viral" post="replication. A well-conserved NS1 sequence, along with appropriate controls,"/>
 <result pre="entire population. A significant number of individuals have defects in" exact="type 1" post="IFN pathways resulting in lack of induction of type"/>
 <result pre="type 1 IFN pathways resulting in lack of induction of" exact="type 1" post="IFNs and/or absence or suboptimal responses to type 1"/>
 <result pre="of type 1 IFNs and/or absence or suboptimal responses to" exact="type 1" post="IFN-mediated signaling. In this population, RIG-I-mediated antiviral effects via"/>
 <result pre="this population, RIG-I-mediated antiviral effects via the 5′-PPP group for" exact="type 1" post="IFN induction will not work. Hence we exploited NS1shRNA-mediated"/>
 <result pre="in Figure 2 using Vero cells that are defective in" exact="type 1" post="IFN signaling cascade. Only NS1shRNAs capped or uncapped were"/>
 <result pre="cell lines, there was a 3.5–4 log reduction in A/Brisbane/59/2007" exact="viral" post="titers when the cells were infected 6, 12, and"/>
 <result pre="7mG-capped NS1shRNA and 5′-PPP-scrambled shRNA are also very effective against" exact="viral" post="replication. 7mG-capped control 9.2 RNA and 7mG-capped scrambled NS1shRNA"/>
 <result pre="(NPsiRNA) of influenza virus, a reduction of 1–2 logs in" exact="viral" post="titer has been reported depending on the amount of"/>
 <result pre="5′-PPP-NS1 silencing RNA and demonstrated only 40%–45% reduction in A/PR/8/34" exact="viral" post="titers in contrast with our 3.5 to 4 log"/>
 <result pre="in contrast with our 3.5 to 4 log reduction in" exact="viral" post="titers.33 The observed poor effectiveness of their approach may"/>
 <result pre="setting in vivo, administration of 5′-PPP-NS1shRNA 24 h prior to" exact="infection" post="resulted in a 2 log reduction in viral titers"/>
 <result pre="prior to infection resulted in a 2 log reduction in" exact="viral" post="titers for 5′-PPP-NS1shRNA, m7G-capped-NS1shRNA, and 5′-PPP-scrambled NS1shRNA (Figure 5A)"/>
 <result pre="setting, when NS1shRNA constructs were administered on the day of" exact="viral infection" post="and 24 h post-infection, there was a reduction of"/>
 <result pre="when NS1shRNA constructs were administered on the day of viral" exact="infection" post="and 24 h post-infection, there was a reduction of"/>
 <result pre="infection and 24 h post-infection, there was a reduction of" exact="viral" post="titers by 2 and 1.5 logs, respectively. However, the"/>
 <result pre="effect was only a 1.5 to 1 log reduction in" exact="viral" post="titers when the shRNAs were administered on days 2"/>
 <result pre="in a similar therapeutic model with A/PR/8/34 challenge, reduction of" exact="viral" post="titers was not statistically significant, which may be because"/>
 <result pre="the dose of the virus they used 4 times the" exact="viral" post="dose that kills 50% of mice (4LD50). Similarly, using"/>
 <result pre="mice (4LD50). Similarly, using 5′-PPP-NPsiRNA, a 1 log reduction in" exact="viral" post="titer was observed.32 Unlike the earlier observations, our study"/>
 <result pre="and showed that a single administration of dual-acting 5′-PPP-NS1shRNA suppresses" exact="viral" post="replication &amp;gt;3 logs in vitro and 2 logs in"/>
 <result pre="up to 24–48 h to have a beneficial effect in" exact="viral" post="titer reduction. Furthermore, the ease of administration by the"/>
 <result pre="earlier and in this report, but also to treat other" exact="viral" post="infectious diseases, including Ebola, and cancer.17,22, 23, 24 Materials"/>
 <result pre="and in this report, but also to treat other viral" exact="infectious diseases," post="including Ebola, and cancer.17,22, 23, 24 Materials and Methods"/>
 <result pre="cancer.17,22, 23, 24 Materials and Methods Cell Lines Human lung" exact="epithelial" post="cells (A549), African green monkey kidney cells (Vero), and"/>
 <result pre="Materials and Methods Cell Lines Human lung epithelial cells (A549)," exact="African" post="green monkey kidney cells (Vero), and MDCK cells were"/>
 <result pre="(H1N1) viruses were obtained from the influenza division Centers for" exact="Disease" post="Control and Prevention (CDC) repository and were propagated in"/>
 <result pre="three algorithms: MFold, SFold, and Oligowalk. MFold identifies the most" exact="stable" post="secondary structure and a neighborhood of less stable structures."/>
 <result pre="algorithms: MFold, SFold, and Oligowalk. MFold identifies the most stable" exact="secondary" post="structure and a neighborhood of less stable structures. SFold"/>
 <result pre="the most stable secondary structure and a neighborhood of less" exact="stable" post="structures. SFold uses a Boltzmann energy sampling algorithm to"/>
 <result pre="sampling algorithm to assess the access probability across the entire" exact="secondary" post="structural folding space. OligoWalk assesses the local folding energy"/>
 <result pre="RIG-I-Mediated Effects and NS1 Silencing Effects Vero cells that lack" exact="type 1" post="IFN genes were grown in six-well tissue culture plates"/>
 <result pre="and protein analysis, and supernatants were collected for determination of" exact="viral" post="titer by plaque assay using MDCK cells, as described"/>
 <result pre="and each treatment was done in duplicate cultures. Western Blot" exact="Total" post="protein was separated on a 4%–20% SDS-PAGE gel (Precise;"/>
 <result pre="protein was separated on a 4%–20% SDS-PAGE gel (Precise; Thermo" exact="Fisher" post="Scientific, Waltham, MA, USA) at a constant current of"/>
 <result pre="purchased from Millipore Sigma (St. Louis, MO, USA). Real-Time RT-PCR" exact="Total" post="RNA was isolated from cells or lung tissue using"/>
 <result pre="s, and extension at 72°C for 30 s for a" exact="total" post="of 45 cycles, and relative mRNA levels were expressed"/>
 <result pre="and reverse 5′-TAG CAC AGC CTG GAT AGC AAC GTA-3′." exact="Mouse" post="primer sets used in this study were: mRIG-I, forward"/>
 <result pre="5′-CGCCCTGTAGGTGAGGTTGAT-3′; mβ-actin, forward 5′-ATGCTCCCCGGGCTGTAT-3′ and reverse 5′-CATAGGAGTCCTTCTGACCCATTC-3′. In Vivo Studies" exact="Female" post="BALB/c mice, 6–12 weeks old (Jackson Laboratories, Bar Harbor,"/>
 <result pre="were challenged on day 0, intranasally, with ten 50% mouse" exact="infectious" post="doses (MID50) of mouse-adapted A/PR/8/34 virus in a final"/>
 <result pre="or labored breathing, which are indicative of morbidity or sickness." exact="Mouse" post="lungs were harvested on day 4 postchallenge and immediately"/>
 <result pre="and have written the manuscript. References References 1collab: Centers for" exact="Disease" post="Control and PreventionEstimated influenza illnesses, medical visits, hospitalizations, and"/>
 <result pre="2016/17 and 2017/18 seasonsEuro Surveill.2420191800666 13TakashitaE.KawakamiC.OgawaR.MoritaH.FujisakiS.ShirakuraM.MiuraH.NakamuraK.KishidaN.KuwaharaT.Influenza A(H3N2) virus exhibiting reduced" exact="susceptibility to" post="baloxavir due to a polymerase acidic subunit I38T substitution"/>
 <result pre="virus is mediated by RIG-I which is regulated by the" exact="viral" post="NS1 proteinCell. Microbiol.9200793093817140406 21DavisW.G.BowzardJ.B.SharmaS.D.WiensM.E.RanjanP.GangappaS.StuchlikO.PohlJ.DonisR.O.KatzJ.M.The 3′ untranslated regions of influenza"/>
 <result pre="delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza" exact="viral" post="replicationProc. Natl. Acad. Sci. USA1072010101721017720498074 25JingH.SuH.C.New immunodeficiency syndromes that"/>
 <result pre="pandemic H1N1 influenza viral replicationProc. Natl. Acad. Sci. USA1072010101721017720498074 25JingH.SuH.C.New" exact="immunodeficiency" post="syndromes that help us understand the IFN-mediated antiviral immune"/>
 <result pre="us understand the IFN-mediated antiviral immune responseCurr. Opin. Pediatr.31201981582031693592 26LevinS.HahnT.Interferon" exact="deficiency" post="syndromeClin. Exp. Immunol.6019852672732408800 27SullivanJ.M.YauE.H.TaggartR.T.ButlerM.C.KolniakT.A.Relieving bottlenecks in RNA drug discovery"/>
 <result pre="macromolecule in biological realmInt. J. Biol. Macromol.118Pt A2018495629847782 29ClarkeD.K.SidhuM.S.JohnsonJ.E.UdemS.A.Rescue of" exact="mumps" post="virus from cDNAJ. Virol.7420004831483810775622 30LieberA.KiesslingU.StraussM.High level gene expression in"/>
 <result pre="cellsGenes Dev.16200294895811959843 32LinL.LiuQ.BerubeN.DetmerS.ZhouY.5′-Triphosphate-short interfering RNA: potent inhibition of influenza A" exact="virus infection" post="by gene silencing and RIG-I activationJ. Virol.862012103591036922787226 33SvancarovaP.SvetlikovaD.BetakovaT.Synergic and"/>
 <result pre="Dev.16200294895811959843 32LinL.LiuQ.BerubeN.DetmerS.ZhouY.5′-Triphosphate-short interfering RNA: potent inhibition of influenza A virus" exact="infection" post="by gene silencing and RIG-I activationJ. Virol.862012103591036922787226 33SvancarovaP.SvetlikovaD.BetakovaT.Synergic and"/>
 <result pre="Global Seasonal Influenza-associated Mortality Collaborator NetworkEstimates of global seasonal influenza-associated" exact="respiratory" post="mortality: a modelling studyLancet39120181285130029248255 36WendelH.A.SnyderM.T.PellS.Trial of amantadine in epidemic"/>
 <result pre="of amantadine in epidemic influenzaClin. Pharmacol. Ther.7196638435325584 37collab: Centers for" exact="Disease" post="Control and PreventionInfluenza antiviral medications: summary for clinicianshttps://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm2019 38BouvierN.M.LowenA.C.PaleseP.Oseltamivir-resistant"/>
 <result pre="lead hammerhead ribozyme candidates against human rod opsin mRNA for" exact="retinal degeneration" post="therapyExp. Eye Res.88200985987919094986 41FroebelB.R.TrujilloA.J.SullivanJ.M.Effects of Pathogenic Variations in the"/>
 <result pre="approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA" exact="disease" post="targetsExp. Eye Res.151201623625527233447 43YauE.H.TaggartR.T.ZuberM.TrujilloA.J.FayaziZ.S.ButlerM.C.SheflinL.G.BreenJ.B.YuD.SullivanJ.M.Systematic screening, rational development, and initial"/>
 <result pre="and S.S.) and intramural research support from the Centers for" exact="Disease" post="Control and Prevention (Atlanta, GA, USA). The findings and"/>
 <result pre="represent the views of the funding agency or Centers for" exact="Disease" post="Control and Prevention. Supplemental Information can be found online"/>
</results>
